AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key expert meeting

13th July 2021 Uncategorised 0

AstraZeneca, FibroGen’s roxadustat hit with tough safety questions in FDA review ahead of key expert meeting
aliu
Tue, 07/13/2021 – 11:16

More: AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key expert meeting
Source: fierce